Patents by Inventor Bruce Sullenger

Bruce Sullenger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250136995
    Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR or EGFR expression and methods of using these splice-switching oligonucleotides to treat cancer.
    Type: Application
    Filed: June 4, 2024
    Publication date: May 1, 2025
    Inventors: Jennifer Freedman, Brendon Patierno, Bonnie LaCroix, Timothy Robinson, Bruce Sullenger, Daniel George, Steven Patierno
  • Patent number: 12071626
    Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR or EGFR expression and methods of using these splice-switching oligonucleotides to treat cancer.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: August 27, 2024
    Assignee: Duke University
    Inventors: Jennifer Freedman, Brendon Patierno, Bonnie LaCroix, Timothy Robinson, Bruce Sullenger, Daniel George, Steven Patierno
  • Publication number: 20240229028
    Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR expression and methods of using these splice-switching oligonucleotides to treat cancer, specifically castrate resistant prostate cancer.
    Type: Application
    Filed: January 2, 2024
    Publication date: July 11, 2024
    Inventors: Jennifer Freedman, Steven Patierno, Daniel George, Bruce Sullenger, Bonnie LaCroix, Brendon Patierno
  • Publication number: 20240226307
    Abstract: Disclosed are POEGMA-aptamer conjugates with a reduced or eliminated host-immune response. An example conjugate includes an aptamer conjugated to a POEGMA having a plurality of side chains, where each side chain includes 1 to 6 monomers of ethylene glycol repeated in tandem. Also disclosed are methods of making the conjugate and methods of using the conjugate. An example method of use includes a method of controlling coagulation in a subject.
    Type: Application
    Filed: February 22, 2022
    Publication date: July 11, 2024
    Inventors: Ashutosh Chilkoti, Bruce Sullenger, Imran Ozer, Angus Hucknall, Juliana Layzer, George Pitoc
  • Publication number: 20240141430
    Abstract: Provided herein are compositions and methods for sorting and/or identifying live cells. The compositions and methods provide for staining of live cells with aptamer so particular cells can be identified within or sorted from a heterogeneous population of live cells and subsequent reversal of the staining to prepare sorted and/or identified cells in their native state.
    Type: Application
    Filed: March 30, 2023
    Publication date: May 2, 2024
    Inventors: Bruce Sullenger, Bethany Gray, Michael Nichols
  • Publication number: 20240131171
    Abstract: Disclosed are POEGMA-aptamer conjugates with a reduced or eliminated host-immune response. An example conjugate includes an aptamer conjugated to a POEGMA having a plurality of side chains, where each side chain includes 1 to 6 monomers of ethylene glycol repeated in tandem. Also disclosed are methods of making the conjugate and methods of using the conjugate. An example method of use includes a method of controlling coagulation in a subject.
    Type: Application
    Filed: February 22, 2022
    Publication date: April 25, 2024
    Inventors: Ashutosh Chilkoti, Bruce Sullenger, Imran Ozer, Angus Hucknall, Juliana Layzer, George Pitoc
  • Patent number: 11965160
    Abstract: Provided herein are aptamers capable of inhibiting the activity of Von Willebrand Factor (VWF). Pharmaceutical compositions comprising these aptamers are also provided. Methods of preventing blood clot formation in a subject by administering the aptamers are provided and methods of treating a blood clot by administering a VWF-targeting agent are also provided.
    Type: Grant
    Filed: January 11, 2021
    Date of Patent: April 23, 2024
    Assignees: Duke University, Ohio State Innovation Foundation
    Inventors: Shahid M. Nimjee, Bruce Sullenger, George A. Pitoc, Juliana Layzer
  • Patent number: 11866689
    Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR expression and methods of using these splice-switching oligonucleotides to treat cancer, specifically castrate resistant prostate cancer.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: January 9, 2024
    Assignee: Duke University
    Inventors: Jennifer Freedman, Steven Patierno, Daniel George, Bruce Sullenger, Bonnie LaCroix, Brendon Patierno
  • Patent number: 11634772
    Abstract: Provided herein are compositions and methods for sorting and/or identifying live cells. The compositions and methods provide for staining of live cells with aptamer so particular cells can be identified within or sorted from a heterogeneous population of live cells and subsequent reversal of the staining to prepare sorted and/or identified cells in their native state.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: April 25, 2023
    Assignee: Duke University
    Inventors: Bruce Sullenger, Bethany Gray, Michael Nichols
  • Publication number: 20230012024
    Abstract: The present application provides for a method for controlling coagulation in a subject in need of extracorporeal membrane oxygenation. The method comprises administering an effective amount of an anticoagulant agent that directly inhibits one or more steps in a coagulation pathway to the subject, wherein the effective amount of the anticoagulant agent is capable of controlling coagulation during extra corporeal membrane oxygenation for a coagulation control time of at least 4 hours.
    Type: Application
    Filed: December 4, 2020
    Publication date: January 12, 2023
    Inventors: Bruce Sullenger, Elisabeth Tracy, Christopher Reed
  • Publication number: 20210395754
    Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR or EGFR expression and methods of using these splice-switching oligonucleotides to treat cancer.
    Type: Application
    Filed: September 1, 2021
    Publication date: December 23, 2021
    Inventors: Jennifer Freedman, Brendon Patierno, Bonnie LaCroix, Timothy Robinson, Bruce Sullenger, Daniel George, Steven Patierno
  • Patent number: 11136584
    Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR or EGFR expression and methods of using these splice-switching oligonucleotides to treat cancer.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: October 5, 2021
    Assignee: Duke University
    Inventors: Jennifer Freedman, Brendon Patierno, Bonnie Lacroix, Timothy Robinson, Bruce Sullenger, Daniel George, Steven Patierno
  • Publication number: 20210024932
    Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR expression and methods of using these splice-switching oligonucleotides to treat cancer, specifically castrate resistant prostate cancer.
    Type: Application
    Filed: March 22, 2019
    Publication date: January 28, 2021
    Applicant: Duke University
    Inventors: Jennifer Freedman, Steven Patierno, Daniel George, Bruce Sullenger, Bonnie Lacroix, Brendon Patierno
  • Patent number: 10889816
    Abstract: Provided herein are aptamers capable of inhibiting the activity of Von Willebrand Factor (VWF). Pharmaceutical compositions comprising these aptamers are also provided. Methods of preventing blood clot formation in a subject by administering the aptamers are provided and methods of treating a blood clot by administering a VWF-targeting agent are also provided.
    Type: Grant
    Filed: September 18, 2017
    Date of Patent: January 12, 2021
    Assignees: DUKE UNIVERSITY, OHIO STATE INNOVATION FOUNDATION
    Inventors: Shahid M. Nimjee, George A. Pitoc, Juliana Layzer, Bruce Sullenger
  • Publication number: 20200095636
    Abstract: Provided herein are compositions and methods for sorting and/or identifying live cells. The compositions and methods provide for staining of live cells with aptamer so particular cells can be identified within or sorted from a heterogeneous population of live cells and subsequent reversal of the staining to prepare sorted and/or identified cells in their native state.
    Type: Application
    Filed: March 23, 2018
    Publication date: March 26, 2020
    Applicant: Duke University
    Inventors: Bruce Sullenger, Bethany Gray, Michael Nichols
  • Publication number: 20180334677
    Abstract: The present disclosure provides methods and compositions for the treatment of cancer. In some aspects, the present disclosure provides splice-switching oligonucleotides that downregulate AR or EGFR expression and methods of using these splice-switching oligonucleotides to treat cancer.
    Type: Application
    Filed: November 4, 2016
    Publication date: November 22, 2018
    Inventors: Jennifer Freedman, Brendon Patierno, Bonnie Lacroix, Timothy Robinson, Bruce Sullenger, Daniel George, Steven Patierno
  • Publication number: 20110118187
    Abstract: The present invention relates, in general, to receptors and to platelet aggregation and, in particular, to a method of inhibiting platelet aggregation using an aptamer that binds to and inhibits the activity of a receptor, such as glycoprotein IIb/IIIa (gpIIb/IIIa), and to aptamers suitable for use in such a method. The invention also relates to antidotes to antiplatelet agents and to methods of using such antidotes to reverse aptamer-induced platelet inhibition. The invention further relates to von Willebrand Factor (VWF) inhibitors, and antidotes therefore, and to methods of using same.
    Type: Application
    Filed: October 19, 2007
    Publication date: May 19, 2011
    Inventors: Bruce Sullenger, Shahid Nimjee, Sabah Oney, Nanette Que-Gewirth
  • Publication number: 20080051339
    Abstract: The biological activity of nucleic acid ligand is regulated (i.e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves, metabolizes or breaks down the nucleic acid ligand while the ligand is still exerting its effect. Modulators of the present invention can be administered in real time as needed based on various factors, including the progress of the patient, as well as the physician's discretion in how to achieve optimal therapy. Thus, this invention provides for the first time a regulatable therapeutic regime in the course of nucleic acid ligand therapy.
    Type: Application
    Filed: April 26, 2007
    Publication date: February 28, 2008
    Applicant: Duke University
    Inventors: Bruce Sullenger, Christopher Rusconi
  • Publication number: 20060246123
    Abstract: The present invention relates, in general, to a method of using aptamers to modulate the immune system and, in method of inhibiting CTLR-4 function and to aptamers suitable for use in such a method.
    Type: Application
    Filed: March 12, 2004
    Publication date: November 2, 2006
    Inventors: Eli Gilboa, Sandra Santulli-Marotto, Bruce Sullenger, Christopher Rusconi
  • Patent number: 7045293
    Abstract: Method for splicing a target nucleic acid molecule with a separate nucleic acid molecule. Such splicing generally causes production of a chimeric protein with advantageous features over that protein naturally produced from the target nucleic acid prior to splicing. The method includes contacting the target nucleic acid molecule with a catalytic nucleic acid molecule including the separate nucleic acid molecule. Such contacting is performed under conditions in which at least a portion of the separate nucleic acid molecule is spliced with at least a portion of the target nucleic acid molecule to form a chimeric nucleic acid molecule. In this method, the catalytic nucleic molecule is chosen so that it is not naturally associated with the separate nucleic acid molecule.
    Type: Grant
    Filed: March 12, 2004
    Date of Patent: May 16, 2006
    Assignee: The Regents of the University of Colorado
    Inventors: Bruce Sullenger, Thomas R. Cech